Effect of polymorphisms in drug metabolism and transportation on plasma concentration of atorvastatin and its metabolites in patients with chronic kidney disease

• Main Authors: Zebin Jiang (Author), Zemin Wu (Author), Ruixue Liu (Author), Qin Du (Author), Xian Fu (Author), Min Li (Author), Yongjun Kuang (Author), Shen Lin (Author), Jiaxuan Wu (Author), Weiji Xie (Author), Ganggang Shi (Author), Yanqiang Peng (Author), Fuchun Zheng (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Dyslipidemia due to renal insufficiency is a common complication in patients with chronic kidney diseases (CKD), and a major risk factor for the development of cardiovascular events. Atorvastatin (AT) is mainly used in the treatment of dyslipidemia in patients with CKD. However, response to the ator...